Overview

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

Status:
RECRUITING

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) prior to surgery. Patients who are enrolled in this trial will receive combination of Non-ablative oligofractionated radiation (NORT) and two cycles of Durvalumab, an immunotherapy drug before their surgery.

Phase:

PHASE2

Details

Lead Sponsor:

Marc de Perrot

Collaborator:

Ozmosis Research Inc.

Treatments:

durvalumab